Study of ZIO-101 in Multiple Myeloma

A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00303199

Enrollment

Registered

2006-03-15

Start date

2006-01-31

Completion date

2007-08-31

Last updated

2012-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Multiple Myeloma, Arsenic, Cancer study, Failed treatment

Brief summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Interventions

DRUGZIO-101 (Darinaparsin)

IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.

Design outcomes

Primary

Measure	Time frame
Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03	6 months
Phase II efficacy using EMBT criteria.	6 months
Safety	6 months

Secondary

Measure	Time frame
Pharmacokinetics of ZIO-101	6 months

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026